Semax vs Selank: Which One Do You Actually Need?

The Short Answer

If you are comparing these two because you are about to buy one from a research vendor, the conventional split will serve you: Selank Explore PeRxSemax/SelankCognitive Clarity & Calm FocusView peptide is the one with a controlled human trial behind its anxiety claim, and Semax is the one Russian neurologists reached for in stroke clinics and attention complaints. If you are comparing them because you are considering a prescription, there is nothing to decide. Both arrive in the same vial.

What almost no comparison page tells you is how thin the ground under that split really is. The two molecules came out of the same laboratory, share a stabilizing tail, and block the same family of enzymes in human blood. One study has ever given both to people and compared what happened, and reading it carefully complicates the tidy accelerator-and-brake story that the ranking pages repeat almost word for word.

Semax vs Selank at a Glance

Same Lab, Same Trick, Different Start

The two are siblings in a literal sense. Both came out of the Institute of Molecular Genetics in Moscow, and both solved the same engineering problem the same way. A short natural peptide does something interesting in the brain but falls apart in the bloodstream within minutes, so the chemists bolted a Pro-Gly-Pro tail onto the end to slow the enzymes that chew peptides from their ends. Do that to a fragment of ACTH and you get Semax. Do it to tuftsin, a fragment of antibody protein described by an American immunologist in 1970, and you get Selank.

That shared design shows in the sequences. Semax is Met-Glu-His-Phe-Pro-Gly-Pro. Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Seven amino acids each, and the last three are identical. The starting material differs, which is where the accelerator-and-brake framing comes from, but the family resemblance is not cosmetic, and it has a consequence the next section gets to.

Where They Overlap

In 2001 a Moscow group tested both peptides against enkephalin-degrading enzymes from human serum. Enkephalins are the body's own opioid-like signaling peptides, and the enzymes that break them down handle other regulatory peptides too. Both inhibited those enzymes dose-dependently. Semax was the more potent, with a half-maximal concentration around 10 micromolar against roughly 20 for Selank, and both beat the reference inhibitors tested alongside them. The authors proposed this shared activity as one mechanism behind both peptides.

Kost NV, Sokolov OYu, Gabaeva MV, et al. "Semax and selank inhibit the enkephalin-degrading enzymes from human serum." Bioorganicheskaia Khimiia. 2001;27(3):180-183. PMID 11443939. View study

That finding is not obscure: the FDA cited the same paper in its 2026 reference list for Semax. It cuts against the premise of the comparison. Two peptides working partly through the same enzymatic route are not a stimulant and a sedative at opposite ends of a spectrum. They are close relatives with different emphases, a less satisfying answer than the search results offer and a more accurate one.

The One Human Head-to-Head

Search PubMed for papers mentioning both peptides and you get eleven results. Most are rodent work, chemistry, or reviews. Exactly one put both molecules into people and compared them, and it is worth more attention than the entire first page of search results gives it.

In 2020, a group at the Mental Health Research Center in Moscow recruited 52 healthy volunteers and scanned them with resting-state functional MRI three times each: before an injection, five minutes after, and twenty minutes after. Participants received Semax, Selank, or placebo. The regions of interest were chosen in advance, and the choice maps neatly onto the marketing: the amygdala, described as one of the key regions for regulating anxiety, and the dorsolateral prefrontal cortex, called the key region for executive functions including working memory. Amygdala for the calm peptide, prefrontal cortex for the focus peptide.

Panikratova YR, Lebedeva IS, Sokolov OY, et al. "Functional Connectomic Approach to Studying Selank and Semax Effects." Doklady Biological Sciences. 2020;490(1):9-11. PMID 32342318. View study

The differences sat between the right amygdala and a region of the right temporal lobe. Both drugs moved that connection, and a follow-up analysis let the authors describe general and specific effects of each peptide on it, which they noted was the first time anyone had done so. The prefrontal region, picked to capture the cognitive story, does not appear in the reported findings at all.

One more detail earns its place: participants were injected, where almost every other human study of either peptide used nasal dosing. For a clinic that prescribes these as a subcutaneous vial, it is the rare piece of human data collected by the route we use.

The animal literature that compared them directly tells a similar story with the same caveats. In a 2017 experiment, rats with chemically induced Parkinson-like damage received Semax or Selank. Neither peptide changed motor activity or defensive behavior. Selank reduced anxiety measures; the report describes no equivalent finding for Semax on those endpoints.

Slominsky PA, Shadrina MI, Kolomin TA, et al. "Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism." Doklady Biological Sciences. 2017;474(1):106-109. PMID 28702721. View study

What Backs Each One

Strip out the direct comparisons and you are left with two separate evidence bases that are not the same size or the same quality, and not in the direction most people assume. Selank has fewer studies but its best one is a controlled clinical trial. Semax has more clinical volume but in designs that are harder to trust.

The Selank trial is the strongest single piece of evidence either peptide has, so its shape matters. Sixty-two patients with generalized anxiety disorder or neurasthenia were split between Selank and medazepam, a benzodiazepine. Both produced similar anxiolytic effects, and the authors reported that Selank additionally had antiasthenic and stimulating effects. Note what is missing: no placebo group, so the trial shows Selank performing like an active drug rather than proving it beats doing nothing. It was published in Russian in 2008.

Zozulia AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48. PMID 18454096. View study

The GABA claim attached to Selank rests on gene expression rather than a receptor binding study. Researchers gave rats either Selank or GABA itself and measured 84 neurotransmission genes in the frontal cortex. Forty-five changed within an hour, twenty-two were still changed at three hours, and the Selank changes correlated positively with the GABA changes. That correlation is the basis for calling Selank an allosteric modulator of the GABA system: a reasonable inference from rat brain tissue, not a measurement in a person.

Volkova A, Shadrina M, Kolomin T, et al. "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission." Frontiers in Pharmacology. 2016;7:31. PMID 26924987. View study

Nasal Research, Injected Prescription

Roughly three thousand US searches a month look for these two as a nasal spray, and the expectation is well founded. Most of the Russian research used nasal dosing, Semax is registered in Russia as nasal drops, and the products sold online are mostly sprays. Surveying the market in 2026, FDA reviewers found sites selling Semax alone and combined with Selank, including a fifty-fifty version offered both as an injectable and as a nasal spray.

The tradeoff is worth stating plainly. A nasal dose takes a shortcut into the brain that an injection does not, and in rats it delivered several times more peptide to brain tissue than an intravenous dose of the same size. What it gives up is dose control, because the pump and container become variables. An injection gives up the shortcut and buys a fixed concentration and a volume you can read off a syringe. Our Semax guide Read nextSemax Peptide: What It Is, Uses, and the EvidenceSemax is a seven-amino-acid peptide designed in Moscow, registered in Russia as nasal drops, and sold in the United States mostly by chemical suppliers. This guide covers what it is, what the studies in rats and in people actually show, what FDA reviewers concluded in 2026, who gets screened out, and why PeRx prescribes it only inside an injected blend with Selank.Read article covers the route question in depth, and where to inject Selank Read nextWhere to Inject Semax/Selank: Sites, Rotation, TimingPeRx sells Selank as part of the Semax/Selank blend, a single vial given as a subcutaneous injection. Standalone intranasal Semax is a different product. This guide covers where to place the blend, how to rotate sites, and why morning timing matters, as of July 2026.Read article covers the vial.

Where the FDA Record Splits Them

Here the two genuinely part company, and no comparison page we found mentions it. Start with what they share. Both appear on the FDA page listing bulk substances nominated for compounding and later withdrawn, with near-identical language for each, warning that compounded drugs containing them may pose a risk of immunogenicity for certain routes because of potential aggregation and peptide impurities. Neither appears in any of the three categories of the FDA document tracking nominated substances, updated May 14, 2026.

The divergence is what happened next. FDA pharmacologists produced a roughly fifty-page assessment of Semax dated May 11, 2026, and on July 24, 2026 the Pharmacy Compounding Advisory Committee voted 8 to 5, with one abstention, to recommend adding it to the list of substances pharmacies may compound under section 503A, against the FDA staff position. Selank was not on the agenda either day. It has never had an agency evaluation, and the Semax review explicitly set it aside, noting that a submitted paper concerned "a different peptide, selank," which was "out of the scope of this evaluation and is, therefore, not further discussed."

U.S. Food and Drug Administration. "FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate)." Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. Evaluation dated May 11, 2026. View study

Anti-doping is thinner than athletes expect, and here the two sit together. Neither peptide is named anywhere in the 2026 World Anti-Doping Agency Prohibited List. The list's S0 class sweeps in any pharmacological substance with no current approval by any governmental health authority for human therapeutic use, which is the provision usually cited for these peptides, though both are registered medicines in Russia. Do not try to resolve that ambiguity alone. Get a written determination from your anti-doping organization before using either, and see peptide therapy for athletes Read nextPeptide Therapy for Athletes: WADA Rules & UseAthletes were among the earliest adopters of peptide therapy, and for good reason. Faster recovery between training sessions, accelerated injury repair, and improved body composition are directly relevant to athletic performance. But there are rules, and understanding the competitive landscape matters as much as the pharmacology.Read article for the wider picture.

Side Effects and Screening

Neither peptide has a measured side-effect rate worth quoting, because nobody has run the studies that would produce one. FDA reviewers noted that adverse events went undiscussed in nearly every Semax study they read, and there is no comparable body of safety reporting for Selank at all. What follows is therefore a description of what is watched for and why, not a table of frequencies.

Two concerns apply to both rather than one. The first is immunogenicity, the possibility that an injected peptide provokes an immune response, which is the specific risk the FDA named for each. The second is bleeding. Russian work comparing anticoagulant effects across several proline-containing peptides examined both, and the FDA flagged possible antithrombotic activity for Semax as a concern for anyone on blood thinners. That question sits open for the pair.

Liapina LA, Pastorova VE, Obergan TIu, et al. "Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application." Izvestiia Akademii Nauk. Seriia Biologicheskaia. 2006;(2):193-203. PMID 16634437. View study

What patients on the injected blend actually report is unremarkable: brief redness or soreness at the injection site, and occasionally feeling wired or sleeping badly if the dose lands too late in the day, which is why it is a morning injection. Those are reports rather than measured rates. Stop and contact a clinician for hives, swelling of the face or throat, trouble breathing, or unusual bruising or bleeding after a dose.

Why We Prescribe the Pair

The case for combining them is practical, and its limits are worth stating. No published trial has tested Semax and Selank together against either alone, so the pairing rests on mechanism and clinic experience rather than evidence that the combination beats its halves. What it does buy is concrete: one vial, one morning injection, one set of screening questions, and a pharmacy preparing a fixed concentration of each instead of two products bought separately and dosed by guesswork.

The logic is that anxiety and concentration are not separate problems for most people who come looking. Worry consumes the attention that focus needs, and a heavy cognitive load generates the stress that feeds the worry. Semax is the activating half and Selank the settling half, and they can share a syringe because neither is a sedative. The fuller argument for the blend sits in the Selank and Semax guide Read nextSelank Peptide: What It Is, What It Does & BenefitsYour immune system already makes a molecule that calms anxiety. Soviet scientists found it in the 1970s, reverse-engineered it, and created two peptides: one that quiets anxiety without sedation, and another that sharpens cognition through BDNF. Both have been prescription medications in Russia since 2009. Combined in a single injectable blend, Selank and Semax cover both sides of the equation: calm and sharp at the same time.Read article , while peptides for anxiety Read nextPeptides for Anxiety: What Works and What's HypeSelank and Semax get talked about as natural anxiety fixes. The reality is more interesting than the skeptics assume and less proven than the enthusiasts claim. Here is which peptides are actually studied for anxiety, what the evidence shows, and how they compare to the medications you already know.Read article and nootropic peptides for brain health Read nextNootropic Peptides for Brain Health (2026)Nootropic is a broad word that covers everything from a cup of coffee to a prescription molecule. This guide narrows it to the peptides people actually ask about for cognition, calm, and sleep. What the research supports, what it does not yet support, and how Semax, Selank, Pinealon, and DSIP differ from one another.Read article weigh it against the alternatives on each side.

If You Are Buying Them Separately

Most Semax and Selank sold in the United States comes from research suppliers, labeled not for human use, with no prescription and no screening. The quality problem that creates is not hypothetical. In 2017 and 2018, Belgium's national health institute analyzed two seized suspicious pharmaceutical preparations and found they contained Selank and Semax. The researchers noted that neither peptide had completed any clinical trial to their knowledge, that both were freely available online as powder for injection or as nasal sprays, and built a laboratory method so control agencies could identify them in future seizures.

Vanhee C, Francotte A, Janvier S, Deconinck E. "The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind." Drug Testing and Analysis. 2020;12(3):371-381. PMID 31667971. View study

The FDA made a related observation from the other direction: surveying sites selling Semax, it found that none indicated whether the product contained the free base or a salt, two forms sold interchangeably under one name. The questions worth asking are which form is in the vial, what it was tested for beyond purity, and whether anyone screened you before you injected it. How to read a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from the screenshot a gray-market vendor pastes into a product page.Read article covers what those reports do and do not include, and research peptides vs prescription peptides Read nextResearch Peptides vs Prescription Peptides (2026)An honest comparison for the patient who already uses peptides, what the 'Not for Human Use' label actually means, the real quality differences, and the practical steps to switch from research-chemical sourcing to a prescription supply.Read article lays out how differently the two channels are regulated.

Semax/Selank

Both peptides in one 5 mL vial at 1 mg/mL each, compounded by a licensed US 503A pharmacy and shipped fully reconstituted and ready to use. One small subcutaneous injection in the morning covers both.

From $299 for a one-month supply. Checkout saves your card without charging it, and the charge only goes through once a provider has approved the prescription.

View Semax/Selank

Common Questions